REPORT ID 4470

United States Conjugate Vaccine Market Report 2017

Publish Date
18-Dec-17
Pages
104
Format
Electronic (PDF)

In this report, the United States Conjugate Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Conjugate Vaccine in these regions, from 2012 to 2022 (forecast).

United States Conjugate Vaccine market competition by top manufacturers/players, with Conjugate Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Bharat Biotech (India)
    Biological E (India)
    CSL Limited (Australia)
    GlaxoSmithKline (U.K.)
    Merck and Company (U.S.)
    Neuron Biotech (U.S.)
    Novartis AG (Switzerland)
    Pfizer (U.S.)
    Sanofi Pasteur (France)

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    By Disease Indication
        Pneumococcal
        Influenza
        Diphtheria Tetanus Pertussis
        Meningococcal
    By Type
        Monovalent
        Multivalen
    By Patient Stage
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Conjugate Vaccine Market Report 2017
1 Conjugate Vaccine Overview
    1.1 Product Overview and Scope of Conjugate Vaccine
    1.2 Classification of Conjugate Vaccine by Product Category
        1.2.1 United States Conjugate Vaccine Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Conjugate Vaccine Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Pneumococcal
        1.2.4 Influenza
        1.2.5 Diphtheria Tetanus Pertussis
        1.2.6 Meningococcal
    1.3 United States Conjugate Vaccine Market by Application/End Users
        1.3.1 United States Conjugate Vaccine Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Medical Center
    1.4 United States Conjugate Vaccine Market by Region
        1.4.1 United States Conjugate Vaccine Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Conjugate Vaccine Status and Prospect (2012-2022)
        1.4.3 Southwest Conjugate Vaccine Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Conjugate Vaccine Status and Prospect (2012-2022)
        1.4.5 New England Conjugate Vaccine Status and Prospect (2012-2022)
        1.4.6 The South Conjugate Vaccine Status and Prospect (2012-2022)
        1.4.7 The Midwest Conjugate Vaccine Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Conjugate Vaccine (2012-2022)
        1.5.1 United States Conjugate Vaccine Sales and Growth Rate (2012-2022)
        1.5.2 United States Conjugate Vaccine Revenue and Growth Rate (2012-2022)

2 United States Conjugate Vaccine Market Competition by Players/Suppliers
    2.1 United States Conjugate Vaccine Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Conjugate Vaccine Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Conjugate Vaccine Average Price by Players/Suppliers (2012-2017)
    2.4 United States Conjugate Vaccine Market Competitive Situation and Trends
        2.4.1 United States Conjugate Vaccine Market Concentration Rate
        2.4.2 United States Conjugate Vaccine Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Conjugate Vaccine Manufacturing Base Distribution, Sales Area, Product Type

3 United States Conjugate Vaccine Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Conjugate Vaccine Sales and Market Share by Region (2012-2017)
    3.2 United States Conjugate Vaccine Revenue and Market Share by Region (2012-2017)
    3.3 United States Conjugate Vaccine Price by Region (2012-2017)

4 United States Conjugate Vaccine Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Conjugate Vaccine Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Conjugate Vaccine Revenue and Market Share by Type (2012-2017)
    4.3 United States Conjugate Vaccine Price by Type (2012-2017)
    4.4 United States Conjugate Vaccine Sales Growth Rate by Type (2012-2017)

5 United States Conjugate Vaccine Sales (Volume) by Application (2012-2017)
    5.1 United States Conjugate Vaccine Sales and Market Share by Application (2012-2017)
    5.2 United States Conjugate Vaccine Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Conjugate Vaccine Players/Suppliers Profiles and Sales Data
    6.1 Bharat Biotech (India)
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Conjugate Vaccine Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Bharat Biotech (India) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Biological E (India)
        6.2.2 Conjugate Vaccine Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Biological E (India) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 CSL Limited (Australia)
        6.3.2 Conjugate Vaccine Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 CSL Limited (Australia) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 GlaxoSmithKline (U.K.)
        6.4.2 Conjugate Vaccine Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 GlaxoSmithKline (U.K.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Merck and Company (U.S.)
        6.5.2 Conjugate Vaccine Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Merck and Company (U.S.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Neuron Biotech (U.S.)
        6.6.2 Conjugate Vaccine Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Neuron Biotech (U.S.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Novartis AG (Switzerland)
        6.7.2 Conjugate Vaccine Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Novartis AG (Switzerland) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Pfizer (U.S.)
        6.8.2 Conjugate Vaccine Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Pfizer (U.S.) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Sanofi Pasteur (France)
        6.9.2 Conjugate Vaccine Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sanofi Pasteur (France) Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview

7 Conjugate Vaccine Manufacturing Cost Analysis
    7.1 Conjugate Vaccine Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Conjugate Vaccine

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Conjugate Vaccine Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Conjugate Vaccine Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Conjugate Vaccine Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Conjugate Vaccine Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Conjugate Vaccine Sales Volume Forecast by Type (2017-2022)
    11.3 United States Conjugate Vaccine Sales Volume Forecast by Application (2017-2022)
    11.4 United States Conjugate Vaccine Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer